Frank Karbe Better Therapeutics, Inc. (BTTX) insider trading activity

BTTX Quotes by TradingView

Frank Karbe is Chief Executive Officer of Better Therapeutics, Inc.. Currently has a direct ownership of 526,516 shares of BTTX, which is worth approximately $0. The most recent transaction as insider was on Dec 18, 2023, when has been sold 62,500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 527K
0% 3M change
0% 12M change
Total Value Held $0

FRANK KARBE Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 18 2023
BUY
Grant, award, or other acquisition
-
62,500 Added 10.61%
526,516 Common Stock
Jul 27 2023
BUY
Open market or private purchase
$100,013 $0.73 p/Share
137,005 Added 24.19%
429,429 Common Stock
Apr 10 2023
BUY
Open market or private purchase
$198,787 $0.82 p/Share
242,424 Added 45.33%
292,424 Common Stock
Sep 15 2022
BUY
Open market or private purchase
$104,500 $2.09 p/Share
50,000 Added 50.0%
50,000 Common Stock

Also insider at

MYOV
Myovant Sciences Ltd. Healthcare
Principal Fin'l & Accounting
PHAT
Phathom Pharmaceuticals, Inc. Healthcare
FK

Frank Karbe

Chief Executive Officer
San Francisco, CA

Track Institutional and Insider Activities on BTTX

Follow Better Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BTTX shares.

Notify only if

Insider Trading

Get notified when an Better Therapeutics, Inc. insider buys or sells BTTX shares.

Notify only if

News

Receive news related to Better Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on BTTX